The Biostatistics Core will provide statistical support for the research conducted in the Glioma SPORE program, including related database and computing requirements. The Core will provide consultation and expertise on the development and implementation of plans for data collection, particularly the coding convention and variable format required for statistical analysis. The Core will contribute to the data management plan, including form design and database requirements, during development of the SPORE-related clinical trials. The Core will provide expertise and resources for data transfer, merging, sharing and security while maintaining the confidentiality of all patient-related protected health information. The Core will provide ready and dedicated access to statistical expertise for the design, planning and conduct of preclinical experiments, clinical trials and correlative tissue and biomarker studies. Analysis of the clinical trials will include interim monitoring, if necessary, including the stopping rules for safety and futility. The Core will also provide statistical expertise for data analysis and interpretation of research studies, including manuscript preparation.
The Biotatistics Core is critical to this research program in order to ensure that the proposed studies will satisfy the prevailing and emerging scientific standards for statistical rigor. Successful translation of the preclinical and clinical studies to patient care can be accomplished only ifthe studies were statistically valid in terms of experimental design, data analysis and overall interpretation.
|Taylor, Jennie W; Dietrich, Jorg; Gerstner, Elizabeth R et al. (2015) Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. J Neurooncol 121:557-63|
|Schmit, Fabienne; Utermark, Tamara; Zhang, Sen et al. (2014) PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. Proc Natl Acad Sci U S A 111:6395-400|
|Cheng, Hailing; Liu, Pixu; Zhang, Fan et al. (2014) A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. Cancer Res 74:15-23|
|Francis, Joshua M; Zhang, Cheng-Zhong; Maire, Cecile L et al. (2014) EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov 4:956-71|
|Sullivan, James P; Nahed, Brian V; Madden, Marissa W et al. (2014) Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov 4:1299-309|
|Maire, Cecile L; Ligon, Keith L (2014) Molecular pathologic diagnosis of epidermal growth factor receptor. Neuro Oncol 16 Suppl 8:viii1-6|
|Wakimoto, Hiroaki; Tanaka, Shota; Curry, William T et al. (2014) Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res 20:2898-909|